Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of the HCV NS5B Prote in.

Waheed Y, Saeed U, Anjum S, Afzal MS, Ashraf M.

Hepat Mon. 2012 Sep;12(9):e6142. doi: 10.5812/hepatmon.6142. Epub 2012 Sep 25.

2.

Sequence comparison and phylogenetic analysis of hepatitis C virus genotype 3 polymerase.

Waheed Y, Bhatti A, Anjum S, Ashraf M.

Mol Med Rep. 2014 Apr;9(4):1266-70. doi: 10.3892/mmr.2014.1926. Epub 2014 Jan 30.

PMID:
24481933
3.

Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis.

Aziz H, Raza A, Murtaza S, Waheed Y, Khalid A, Irfan J, Samra Z, Athar MA.

Int J Infect Dis. 2013 Apr;17(4):e247-53. doi: 10.1016/j.ijid.2012.09.017. Epub 2012 Nov 22.

4.

Sequence analysis of the core gene of 14 hepatitis C virus genotypes.

Bukh J, Purcell RH, Miller RH.

Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43.

5.

Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase.

Qin W, Yamashita T, Shirota Y, Lin Y, Wei W, Murakami S.

Hepatology. 2001 Mar;33(3):728-37.

PMID:
11230755
6.

Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.

Lodrini S, Bagaglio S, Canducci F, De Mitri MS, Andreone P, Loggi E, Lazzarin A, Clementi M, Morsica G.

J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):198-204.

PMID:
14518724
7.

Global consensus sequence development and analysis of dengue NS3 conserved domains.

Ayub A, Ashfaq UA, Idrees S, Haque A.

Biores Open Access. 2013 Oct;2(5):392-6. doi: 10.1089/biores.2013.0022.

8.
9.

Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy.

Wu JZ, Hong Z.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):207-19. Review.

PMID:
14529354
10.

Mutational Analysis of Hepatitis C Virus NS5B in the Subgenomic Replicon Cell Culture.

Ma Y, Shimakami T, Luo H, Hayashi N, Murakami S.

J Biol Chem. 2004 Jun 11;279(24):25474-82. Epub 2004 Mar 22.

11.

Selection and application of serotypical synthetic peptides derived from hepatitis C virus NS5A region.

Dou XG, Zhang L, Li ZW, Feng GH, Chang J, Fildes H, Khudyakov Y.

Chin Med J (Engl). 2007 Jul 5;120(13):1159-65.

PMID:
17637245
12.

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.

Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM.

Hepatology. 2003 Oct;38(4):869-78.

PMID:
14512874
13.
14.

Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions.

Walewski JL, Gutierrez JA, Branch-Elliman W, Stump DD, Keller TR, Rodriguez A, Benson G, Branch AD.

RNA. 2002 May;8(5):557-71.

15.

RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region.

Yamashita T, Kaneko S, Shirota Y, Qin W, Nomura T, Kobayashi K, Murakami S.

J Biol Chem. 1998 Jun 19;273(25):15479-86.

19.

No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients.

Di Lello FA, Macias J, Plaza Z, García-Rey S, Soriano V, Cifuentes C, González Mdel M, Parra-Sánchez M, Labarga P, Recio E, Poveda E, Pineda JA.

Antiviral Res. 2012 Aug;95(2):67-71. doi: 10.1016/j.antiviral.2012.05.016. Epub 2012 Jun 7.

PMID:
22683722
20.

Supplemental Content

Support Center